drugset / Trial / NCT03245996
The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker
NaSingle-groupSingle-blindBasic science
Summary
This study is divided into two parts: * The first part evaluates the acute effect of non-pharmacological heart rate change on central hemodynamic parameters noninvasively in sick sinus syndrome patients with a permanent cardiac pacemaker * The second part evaluates the acute effects of atenolol, nebivolol and ivabradine on central hemodynamic parameters noninvasively in sick sinus syndrome patients with a permanent cardiac pacemaker at different pacing rate levels
Timeline
- Start
- 2015-06
- Primary completion
- 2016-09
- Completion
- 2016-09
Publications
- Teeaar T, Serg M, Paapstel K, Vahi M, Kals J, Cockcroft JR, Zilmer M, Eha J, Kampus P. Atenolol's Inferior Ability to Reduce Central vs Peripheral Blood Pressure Can Be Explained by the Combination of Its Heart Rate-Dependent and Heart Rate-Independent Effects. Int J Hypertens. 2020 Apr 26;2020:4259187. doi: 10.1155/2020/4259187. eCollection 2020.
- Teeaar T, Serg M, Paapstel K, Kals J, Kals M, Zilmer M, Eha J, Kampus P. Heart rate reduction decreases central blood pressure in sick sinus syndrome patients with a permanent cardiac pacemaker. J Hum Hypertens. 2018 May;32(5):377-384. doi: 10.1038/s41371-018-0051-4. Epub 2018 Mar 27.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atenolol | Other / unclassified | 50 mg | Oral |
| Subject | Atenolol | Other / unclassified | 100 mg | Oral |
| Subject | Ivabradine | Small molecule | 5 mg | Oral |
| Subject | Ivabradine | Small molecule | 7.5 mg | Oral |
| Subject | Nebivolol | Other / unclassified | 5 mg | Oral |
Indications
No indication recorded.